secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARDELYX, INC. (ARDX)
CIK:        0001437402
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001628280-22-028174
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ardelyx Q3 2022 net loss $22.9M; IBSRELA sales $4.9M; expects $35M Japan milestone
--------------------------------------------------------------------------------

- Net loss of $22.9M ($0.14 per share) versus $43.6M ($0.42) in Q3 2021; narrowed 47%.
- IBSRELA net product sales of $4.9M for Q3 2022, six months into launch.
- Cash, equivalents and investments $90.6M at Sept 30, 2022, down from $116.7M at Dec 31, 2021.
- Kyowa Kirin submitted tenapanor NDA in Japan; Ardelyx expects aggregate $35M milestones in Q4 2022.
- FDA Advisory Committee for XPHOZAH (tenapanor) scheduled for November 16, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1437402/000162828022028174/0001628280-22-028174-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1437402/000162828022028174/ardx-20221103.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-028174

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer